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Abstract 
 
 This research intends to address the issue of non-alcoholic fatty liver disease. This 
disease is accompanied by the accumulation of fat in the liver that can result in inflammation of 
the liver, cirrhosis, steatohepatitis (NASH), and potentially even liver failure. The increase in 
obesity in the United States has led to a rise in the number of people affected by this disease, 
which demonstrates the demand for research in this field. A proposed mechanism for mitigating 
both alcoholic and non-alcoholic liver fibrosis involves the CB1 and CB2 cannabinoid receptors 
found in the liver. While CB1 receptors can facilitate liver fibrosis, the antagonists can be anti-
fibrotic. CB2 receptor agonists have also shown to be anti-fibrotic as well. Based on these 
findings, this research hypothesizes that a compound which contains both CB1 antagonist 
activity and CB2 agonist activity would be highly effective in attenuating liver fibrosis. 
However, research has demonstrated that CB1 antagonists have adverse effects on the central 
nervous system – the brain and spinal cord. Therefore, the hypothesized compound should not be 
able to penetrate the central nervous system, but instead affect only the peripheral nervous 
system. This research focuses on tethering a peripherally selective CB1 antagonist with one of 
four different compounds with known CB2 agonist activity. Tethering these compounds together 
could affect both CB1 and CB2 receptors, thus rendering the compound more effective. Once 
synthesized, these compounds will undergo testing to determine their effect on the cannabinoid 
receptors and liver fibrosis. This research should serve as the basis of cannabinoid receptor 
modulator development, potential NASH treatment, and potentially develop interest in the liver 
fibrosis field.  
